- Home
- BNR
as of 07-06-2026 10:21am EST
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
| Founded: | 2014 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 76.5M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 20.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.51 - $41.72 | Next Earning Date: | 06-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 111.65% | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered BNR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Burning Rock Biotech Limited (BNR)
Director
Avg Cost/Share
$8.00
Shares
24,900
Total Value
$199,090.44
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$8.00
Shares
250,000
Total Value
$2,000,000.00
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$7.50
Shares
5,990
Total Value
$44,920.21
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$7.45
Shares
104,650
Total Value
$779,673.90
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$9.00
Shares
111,110
Total Value
$999,956.67
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$9.25
Shares
210,000
Total Value
$1,942,143.00
Owned After
18,404,086
SEC Form 4
Director
Avg Cost/Share
$8.74
Shares
24,760
Total Value
$216,387.54
Owned After
18,404,086
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Han Yusheng | BNR | Director | Jun 26, 2026 | Buy | $8.00 | 24,900 | $199,090.44 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 24, 2026 | Buy | $8.00 | 250,000 | $2,000,000.00 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 23, 2026 | Buy | $7.50 | 5,990 | $44,920.21 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 22, 2026 | Buy | $7.45 | 104,650 | $779,673.90 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 16, 2026 | Buy | $9.00 | 111,110 | $999,956.67 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 12, 2026 | Buy | $9.25 | 210,000 | $1,942,143.00 | 18,404,086 | |
| Han Yusheng | BNR | Director | Jun 11, 2026 | Buy | $8.74 | 24,760 | $216,387.54 | 18,404,086 |
Compare BNR vs Leading Stocks
See how BNR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BNR Burning Rock Biotech Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.